Via: GlobeNewsWire
SUNNYVALE, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, announced today the commencement of a proposed underwritten public offering of $100 million of shares of its common stock. $75 million of the shares in the offering are being offered for sale by Silk Road Medical and $25 million of the shares are being offered for sale by certain selling securityholders. In addition, the selling securityholders expect to grant the underwriters a 30-day option to purchase up to an additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Silk Road Medical intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Silk Road Medical, to expand its sales force and operations, increase research and development activities, conduct or sponsor clinical studies and trials, lease new facilities, expand internationally, and to provide for working capital and other general corporate purposes. Silk Road Medical may use a portion of the net proceeds to repay debt or acquire complimentary products, technologies, intellectual property or businesses; however, Silk Road Medical currently does not have any agreements or commitments to complete any such transactions and is not involved in negotiations regarding such transactions.
Read More: https://www.globenewswire.com/news-release/2020/05/05/2027940/0/en/Silk-Road-Medical-Announces-Proposed-Public-Offering-of-Common-Stock.html
RSS Feed
